宫颈癌术前介入化疗的效果分析  

Application of neoadjuvant chemotherapy in cervical carcinoma

作　　者：陆杲川[1] 徐军[1] 孙蕾[1] 林晓[1] 张国玲[2] 

机构地区：[1]上海市第八人民医院妇产科,上海市200235 [2]复旦大学附属肿瘤医院妇科

出　　处：《中国基层医药》2008年第4期635-637,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的评价术前介入化疗对宫颈癌的临床疗效。方法对68例宫颈癌患者采用Seldinger穿刺插管技术，应用顺铂（DDP）、表阿霉素（EPI）和博莱霉索（BLM）进行介入化疗．观察其疗效及不良反应。结果68例宫颈癌患者通过术前新辅助介入化疗1～3个疗程后，临床症状缓解率为100％，Ⅰb～Ⅱa期100％（40／40）、Ⅱb期90．9％（20／22），Ⅲa期50％（2／4）。宫颈癌患者化疗后顺利完成根治手术，手术切除率91．2％，仅有6例中、晚期宫颈癌患者无法手术。结论宫颈癌术前介入化疗可以改善临床症状，缩减肿瘤体积和范围，降低肿瘤分期以及提高手术切除率。Objective To evaluate the therapeutic efficacy of neoadjuvant chemotherapy in cervical carcinoma. Methods TAC（DDP,EPI and BLM） was applied in 68 patients with cervical carcinoma. Therapeutic efficacy and side effects were documented. Results After 1 --3 cycles of neoadjuvant chemotherapy, clinical syraptoms remission rates reached 100% ,response rate were 100% （40/40） in Ⅰ b-- Ⅱ a,90.9% （20/22） in Ⅱ b and 50% （2/4） in Ⅲ a,respecrively. Radical resection reached 91.2 % ,and only 6 patients of advanced disease failed to radical resection and turned to radiotherapy. Conclusion Neoadjuvant chemotherapy is a safe and effective therapeutic option which could alleviate clinical symptoms, decrease tumor size, down-staging and increase the radical resection rate.

关 键 词：宫颈肿瘤 化学疗法 肿瘤 局部灌注 顺铂 术前用药法 

分 类 号：R737[医药卫生—肿瘤]